Explore the effect of psilocybin on depression and anxiety
DOI:
https://doi.org/10.61173/rcg8me57Keywords:
Psilocybin, psychedelics, depression, anxi-ety, pathologyAbstract
Psilocybin, also known as “magic mushrooms,” is naturally found in psychedelic compound from different types of mushrooms. The utility of psilocybin for spiritual and therapeutic purposes has already go through several centuries. Scientific research on these compounds gained traction in the mid-20th century, the increasing interest in the possible therapeutic benefits of psilocybin has led to more discoveries, including its use in the treatment of major depression disorder, anxiety disorder, addiction, and end-of-life distress. Research on the effects and safety of psilocybin is ongoing, but preliminary studies have shown promising results. Psilocybin has the potential to revolutionize the way we treat mental health disorders and support overall well-being. Sewell and colleagues suggest that for patients with cluster headaches, psilocybin could make an effective use in the cure or prevention of the regular appearance of cluster headaches. Other than this exciting exploration, treatment of depression and anxiety disorder is also worth discussion. This essay suggests that psilocybin is useful in depression treatment, and is more suitable as a preventive rather than a therapeutic drug in the course of treatment.
References
Haas, A., & Woolley, J. (2024). Participant reports of mindfulness, posttraumatic growth, and social connectedness in psilocybin-assisted group therapy: An interpretive phenomenological analysis. Journal of Humanistic Psychology, 64(4), 564-591. https://doi. org/10.1177/00221678211022949 Carhart-Harris, R.L.; Erritzoe, D.; Williams, T.; Stone, J.M.; Reed, L.J.; Colasanti, A.; Tyacke, R.J.; Leech, R.; Malizia, A.L.; Murphy, K.; et al. Neural correlates of the psychedelic state as determined by fMRI studies with
psilocybin. Proc. Natl. Acad. Sci. USA 2012, 109, 2138– 2143. Coull, J.T.; Cheng, R.-K.; Meck, W.H. Neuroanatomical and Neurochemical Substrates of Timing. Neuropsycho-
pharmacology 2010, 36, 3–25.
Felsch, C. L., & Kuypers, K. P. (2022). Don’t be afraid, try to meditate-potential effects on neural activity and connectivity of psilocybin-assisted mindfulness-based intervention for social anxiety disorder: A systematic review. Neuroscience & Biobehavioral Reviews, 139, 104724. https://doi.org/10.1016/j.neubiorev.2022.104724 Geppert C. Psychedelics and the Military: What a Long, Strange Trip It’s Been. Fed Pract. 2022 Oct;39(10):398- 399. doi: 10.12788/fp.0332. Epub 2022 Oct 9. PMID: 36744014; PMCID: PMC9896363. Goldberg, S. B., Pace, B. T., Nicholas, C. R., Raison, C.
L., & Hutson, P. R. (2020). The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry research, 284, 112749. https://doi. org/10.1016/j.psychres.2020.112749 Goldberg, S. B., Pace, B. T., Nicholas, C. R., Raison, C.
L., & Hutson, P. R. (2020). The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry research, 284, 112749. https://doi. org/10.1016/j.psychres.2020.112749 Grandjean, J.; Buehlmann, D.; Buerge, M.; Sigrist, H.; Seifritz, E.; Vollenweider, F.X.; Pryce, C.R.; Rudin, M. Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in mice. Neuro-
Image 2021, 225. Hare, Bryan D., and Ronald S. Duman. “Prefrontal Cortex Circuits in Depression and Anxiety: Contribution of Discrete Neuronal Populations and Target Regions.”
Molecular Psychiatry, vol. 25, no. 11,2020, pp. 2742-58. doi:10.1038/s41380-020-0685-9. Harris, Jocelyn E., and Janice J. Eng. “Goal priorities identified through client-centered measurement in individuals with chronic stroke.” Physiotherapie Canada, vol.56,
no.3, 2004, pp. 171-6. doi:10.2310/6640.2004.00017. Dean&Francis Yutong Song Johnson, M.W., Griffiths, R.R. Potential Therapeutic Effects of Psilocybin. Neurotherapeutics 14, 734–740 (2017). https://doi.org/10.1007/s13311-017-0542-y3 Lowe, H., Toyang, N., Steele, B., Valentine, H., Grant, J.,
Ali, A., ... & Gordon, L. (2021). The therapeutic potential of psilocybin. Molecules, 26(10), 2948. https://doi. org/10.3390/molecules26102948 Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado,
P. L. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. Journal of clinical Psychiatry, 67(11), 1735-1740. Nichols, D.E. Structure-Activity Relationships of Serotonin 5-HT2A Agonists. Wiley Interdiscip. Rev. Membr.
Transp. Signal. 2012, 1, 559–579.
NIDA. 2024, January 24. Psilocybin (Magic Mushrooms). Retrieved from https://nida.nih.gov/research-topics/psilo-
cybin-magic-mushrooms on 2024, August 27 Plourde, L., Chang, S. L., Farzin, H., Gagnon, P., Hébert,
J., Foxman, R., ... & P3A Study Group. (2024). Social acceptability of psilocybin-assisted therapy for existential distress at the end of life: A population-based survey. Palliative Medicine, 38(2), 272-278. https://doi. org/10.1177/02692163231222430 Preller, K. H., Duerler, P., Burt, J. B., Ji, J. L., Adkinson, B.,
Stämpfli, P., ... & Vollenweider, F. X. (2020). Psilocybin induces time-dependent changes in global functional connectivity. Biological psychiatry, 88(2), 197-207. Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., Mletzko, T., …
Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/ jama.2023.14530 Sakashita, Y.; Abe, K.; Katagiri, N.; Kambe, T.; Saitoh, T.; Utsunomiya, I.; Horiguchi, Y.; Taguchi, K. Effect of Psilocin on Extracellular Dopamine and Serotonin Levels in the Mesoaccumbens and Mesocortical Pathway in Awake
Rats. Biol. Pharm. Bull. 2015, 38, 134–138. Schindler EA, Gottschalk CH, Weil MJ, Shapiro RE, Wright DA, Sewell RA. Indoleamine hallucinogens in cluster headache: results of the Clusterbusters medication use survey. J Psychoact Drugs 2015;47:372-381. Schultes, R.E.; Hofmann, A.; Rätsch, C. Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers; Healing Arts Press: Fairfield, CT, USA, 1998; p. 208.
Sewell RA, Halpern JH, Pope HG. (2006). Response of cluster headache to psilocybin and LSD. Neurology 2006;66:1920-1922. https://doi.org/10.1212/01. wnl.0000219761.05466.43 Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. Journal of Psychopharmacology. 2011;25(11):1434- 1452. doi:10.1177/0269881110382466 Tiffin, Peter A., et al. “A Review of Psychological and Pharmacological Treatments for Generalized Anxiety Disorder.” Expert Opinion on Pharmacotherapy, vol. 19, no. 4, 2018, pp. 355-368.
Tylš, F., Páleníček, T., & Horáček, J. (2014). Psilocybin– summary of knowledge and new perspectives. European Neuropsychopharmacology, 24(3), 342-356. https://doi. org/10.1016/j.euroneuro.2013.12.006 Varker, T., Watson, L., Gibson, K., Forbes, D., & O’Don-
nell, M. L. (2021). Efficacy of psychoactive drugs for the treatment of posttraumatic stress disorder: a systematic review of MDMA, ketamine, LSD and psilocybin. Journal of psychoactive drugs, 53(1), 85-95. Wackermann, J., Wittmann, M., Hasler, F., & Vollenweider,
F. X. (2008). Effects of varied doses of psilocybin on time interval reproduction in human subjects. Neuroscience letters, 435(1), 51-55.
Whelan, A., & Johnson, M. I. (2018). Lysergic Acid Diethylamide and Psilocybin for the Management of Patients with Persistent Pain: a Potential Role. Pain Management, 8(3), 217–229. https://doi.org/10.2217/pmt-2017-0068 Yu, C. L., Yang, F. C., Yang, S. N., Tseng, P. T., Stubbs, B.,
Yeh, T. C., ... & Liang, C. S. (2021). Psilocybin for end-oflife anxiety symptoms: a systematic review and meta-analysis. Psychiatry Investigation, 18(10), 958. https://doi. org/10.30773/pi.2021.0209
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
